Education
About Us
Working with TipRanks
Follow Us
enGene Holdings (ENGN)
NASDAQ:ENGN
ENGN Analyst Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ENGN Stock 12 Month Forecast
Average Price Target
$22.56
▲(224.14% Upside)
| Highest Price Target$33.00 | Average Price Target$22.56 | Lowest Price Target$10.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Citizens JMP
$18→$21
Buy
201.72%
Upside
Reiterated
11/12/25
Wells Fargo
$25
Buy
259.20%
Upside
Reiterated
11/12/25
Oppenheimer
$30→$33
Buy
374.14%
Upside
Reiterated
11/12/25
Morgan Stanley
$18
Buy
158.62%
Upside
Reiterated
11/12/25
UBS
$10
Hold
43.68%
Upside
Reiterated
11/12/25
Guggenheim
$30
Buy
331.03%
Upside
Reiterated
11/11/25
H.C. Wainwright
$25
Buy
259.20%
Upside
Reiterated
11/11/25
Promising Advancements in enGene Holdings' Clinical Trials Justify Buy RatingValuation and risks to achievement of price target. Our 12-month price target of $25 is based on an equally weighted composite of (a) 32.3/share, as a 20x multiple of taxed and diluted FY34 GAAP EPS of $4.48 discounted at 12%, and (b) an NPV of $18.4/ share (discount rate 12.0%, growth rate 3.0%). The assumptions are in line with the expected P/E multiple and discount rate of an early development-stage biopharmaceutical company. Risks to achieving our price target include the following: 1) Clinical risk.
Raymond James
$23→$27
Buy
287.93%
Upside
Reiterated
11/11/25
Leerink Partners
$14
Buy
101.15%
Upside
Reiterated
09/12/25
Piper Sandler
$26
Buy
273.56%
Upside
Reiterated
03/11/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Citizens JMP
$18→$21
Buy
201.72%
Upside
Reiterated
11/12/25
Wells Fargo
$25
Buy
259.20%
Upside
Reiterated
11/12/25
Oppenheimer
$30→$33
Buy
374.14%
Upside
Reiterated
11/12/25
Morgan Stanley
$18
Buy
158.62%
Upside
Reiterated
11/12/25
UBS
$10
Hold
43.68%
Upside
Reiterated
11/12/25
Guggenheim
$30
Buy
331.03%
Upside
Reiterated
11/11/25
H.C. Wainwright
$25
Buy
259.20%
Upside
Reiterated
11/11/25
Promising Advancements in enGene Holdings' Clinical Trials Justify Buy RatingValuation and risks to achievement of price target. Our 12-month price target of $25 is based on an equally weighted composite of (a) 32.3/share, as a 20x multiple of taxed and diluted FY34 GAAP EPS of $4.48 discounted at 12%, and (b) an NPV of $18.4/ share (discount rate 12.0%, growth rate 3.0%). The assumptions are in line with the expected P/E multiple and discount rate of an early development-stage biopharmaceutical company. Risks to achieving our price target include the following: 1) Clinical risk.
Raymond James
$23→$27
Buy
287.93%
Upside
Reiterated
11/11/25
Leerink Partners
$14
Buy
101.15%
Upside
Reiterated
09/12/25
Piper Sandler
$26
Buy
273.56%
Upside
Reiterated
03/11/25
Best Analysts Covering enGene Holdings
1 Month
xxx
Success Rate
6/11 ratings generated profit
Average Return
+3.93%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of +3.93% per trade.
3 Months
xxx
Success Rate
4/11 ratings generated profit
Average Return
-9.95%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 36.36% of your transactions generating a profit, with an average return of -9.95% per trade.
1 Year
Success Rate
5/11 ratings generated profit
Average Return
-14.93%
reiterated a buy rating 2 months ago
Copying Mani Foroohar's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -14.93% per trade.
2 Years
xxx
Success Rate
6/11 ratings generated profit
Average Return
-9.49%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 54.55% of your transactions generating a profit, with an average return of -9.49% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ENGN Analyst Recommendation Trends
Rating
Mar 25
Apr 25
Jun 25
Sep 25
Nov 25
Strong Buy
8
8
14
16
22
Buy
0
0
0
0
0
Hold
2
2
1
1
1
Sell
3
1
1
0
0
Strong Sell
0
0
0
0
0
total
13
11
16
17
23
Each month's total comprises the sum of three months' worth of ratings.
ENGN Financial Forecast
ENGN Stock Forecast FAQ
What is ENGN’s average 12-month price target, according to analysts?
Based on analyst ratings, enGene Holdings’s 12-month average price target is 22.56.
What is ENGN’s upside potential, based on the analysts’ average price target?
enGene Holdings has 224.14% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ENGN a Buy, Sell or Hold?
enGene Holdings has a consensus rating of Strong Buy which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
What is enGene Holdings’s price target?
The average price target for enGene Holdings is 22.56. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $33.00 ,the lowest forecast is $10.00. The average price target represents 224.14% Increase from the current price of $6.96.
The highest analyst price target is $33.00 ,the lowest forecast is $10.00. The average price target represents 224.14% Increase from the current price of $6.96.
What do analysts say about enGene Holdings?
enGene Holdings’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of ENGN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.